RECURRENT NON-HODGKIN LYMPHOMA
Clinical trials for RECURRENT NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for RECURRENT NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New 'Triple-Target' immune therapy enters human testing for tough blood cancers
Disease control Recruiting nowThis early-stage trial is testing the safety and best dose of a new type of CAR-T cell therapy. The therapy uses a patient's own immune cells, modified to attack three different markers (CD19, CD20, CD22) found on cancer cells. It is for adults with certain advanced blood cancers…
Matched conditions: RECURRENT NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated Apr 04, 2026 06:51 UTC
-
New hope for kids with tough cancers: experimental drug trial opens
Disease control Recruiting nowThis study is testing a new drug called tegavivint in children and young adults whose solid tumors have come back or have not responded to other treatments. The main goals are to find the safest dose, understand the side effects, and see if the drug can help shrink tumors. Tegavi…
Matched conditions: RECURRENT NON-HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC
-
Custom immune cells fight blood cancers after transplant
Disease control Recruiting nowThis study tests a personalized immune cell therapy for patients with blood cancers like leukemia, lymphoma, and myeloma. After receiving chemotherapy and a cord blood transplant, patients get infusions of natural killer (NK) cells—immune cells that may kill remaining cancer cell…
Matched conditions: RECURRENT NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC
-
New CAR-T therapy trial targets Tough-to-Treat HIV-Related cancers
Disease control Recruiting nowThis early-stage study is testing a personalized immune therapy called axicabtagene ciloleucel (a type of CAR-T) for people with HIV who have an aggressive form of B-cell lymphoma that has returned or not responded to prior treatments. The main goals are to check if the treatment…
Matched conditions: RECURRENT NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: AIDS Malignancy Consortium • Aim: Disease control
Last updated Mar 18, 2026 14:40 UTC